As a general guideline, Semaglutide GLP-1 injections are typically prescribed to individuals with a BMI of 30 or above or 27 and above with at least one weight-related condition, such as high cholesterol, osteoarthritis, or sleep apnea
And we dont know the long-term consequences these drugs might have for healthy-weight people who take them for weight loss
Currently, we highly recommend the Hi-Affi GLP1R cell line to our customers around the world
[170] [171] In June 2025, the European Medicines Agency recommended that the product information for semaglutide medicines be updated to include non-arteritic anterior ischemic optic neuropathy (NAION) as a very rare side effect, [172] while the World Health Organization concluded that the risk management plan for semaglutide should be revised to include NAION as a potential risk
Autoantibodies to a 68/48 kDa protein in chronic fatigue syndrome and primary fibromyalgia: a possible marker for hypersomnia and cognitive disorders
These symptoms are generally mild to moderate in severity and tend to diminish over time as physiologic adaptation occurs